教育经历:
1. 2019.07-2020.06,澳大利亚悉尼健康科学研究院,访问学者
2. 2010/10-2012/01,美国范德堡大学医学中心,博士后研究
3. 2004/09–2007/06,第一军医大学,药理学,获博士学位
4. 2001/09–2004/06,第一军医大学, 药剂学,获硕士学位
5.1989/09–1993/06,广州中医药大学,中药学,获学士学位
科研与学术工作经历:
1. 2015/07-至今,南方医科大学,南方医院药学部副主任:分管科研与医院制剂
2. 2009/12-至今,南方医科大学,南方医院药学部主任药师、硕士导师
3. 2005/12-2009/11,南方医科大学,南方医院药学部副主任药师
4. 1998/08-2005/11,第一军医大学,南方医院药学部主管药师
5. 1996/07-1998/07,第一军医大学,南方医院药学部药师
6. 1993/07-1996/06,第一军医大学委派驻珠海筹建药厂,药师
综合情况(包括主要工作领域、学术专长、学术贡献、主要成就等):
本人一线药、教、研工作29年,熟悉药学部门科研、制剂生产、药品供应及临床药学工作。2015年至今作为南方医院药学部副主任,分管科研与医院制剂。科研方面,特别在中药与天然药物内分泌代谢、糖尿病、脂肪肝药剂与药理学研究方面有较高的造诣。2018年作为重大新药创制“国家科技重大专项” 子课题负责人,新药常通口服液已进入III期临床研究;2013年、2015年分别主持的广东省和广州市重大新药创制科技攻关课题:防治高泌乳素血症的中药新药研制(省150万元,市100万元),已完成临床前研究,并获国家新药临床试验批件。本人2009年获国家留学基金委出国留学资助及2010年获南方医院杰出青年人才出国留学专项基金资助,于2010年在美国范德堡大学完成博士后研究工作;2018年再次获得公派出国留学基金资助,于2019年7月出访澳大利亚悉尼健康科学研究院,为期1年。
近年作为主持人获得15项国家、省市级基金课题,参与科研课题12项,共获可支配经费600余万元。获省部级科技进步一等奖2项、二等奖3项、三等奖2项,国家中药第6类新药临床批件2项。在国内外发表学术论文120篇(SCI 22篇);获国际及全国优秀论文奖2项,其中二等奖1项、优秀论文奖1项。国家发明专利4项。主编专著2部、副主编1部、参编4部。获中华医学会临床药学分会首届“优秀临床药师”称号。培养多名硕士研究生。
[1] Chengliang Wang,Liying Ren, Shankang Chen, Huihui Zheng, Yifan Yang, Tieguang Gu, Yuhao Li*, Chunxia Wang*. Longdan Xiegan Tang attenuates liver injury and hepatic insulin resistance by regulating the angiotensin-converting enzyme 2/Ang (1-7)/Mas axis-mediated anti-inflammatory pathway in rats. Journal of Ethnopharmacology, 274(2021) 114072 (IF5.195, 一区)
[2] Chunxia Wang*#, Chengliang Wang#, Liying Ren, Shankang Chen, Wen-Hua Chen*, Yuhao Li. The protein kinase D1-mediated inflammatory pathway is involved in olanzapine-induced impairment of skeletal muscle insulin signaling in rats. Life Sciences, 270(2021)119037 (IF6.780, 二区)
[3]Xiaoqian Huang#, Liying Ren#, Lianbing Hou, Hua Fan, Chengliang Wang, Chunxia Wang*, Yuhao Li*. Paeoniflorin ameliorates antipsychotic-induced hyperprolactinemia in rats by attenuating impairment of the dopamine D2 receptor- and TGF-β1 signaling pathways in the hypothalamus and pituitary. Journal of Ethnopharmacology, 257(2020) 112862 (IF5.195, 一区)
[4] Haixing Feng#, Yanling He#, Lei La, Chuqi Hou, Luyao Song, Qin Yang, Fuling Wu, Wenqin Liu, Lianbing Hou*, Yan Li, Chunxia Wang*, Yuhao Li.The flavonoid-enriched extract from the root of Smilax china L. inhibits inflammatory responses via the TLR-4-mediated signaling pathway. Journal of Ethnopharmacology, 256 (2020) 112785(IF5.195, 一区)
[5] Liying Ren#, Wenqin Liu#, Chengliang Wang, Yifan Yang, Xiaoqian Huang, Chunxia Wang*, Yuhao Li*. The ancient Chinese formula Longdan Xiegan Tang improves antipsychotic-induced hyperprolactinemia by repairing the hypothalamic and pituitary TGF-β1 signaling in rats. Journal of Ethnopharmacology, 254 (2020) 112572 .(IF5.195, 一区)
[6] Qin Yang#, Wenqin Liu#, Dongmei Sun, Chunxia Wang, Yangxue Li, Xiaoli Bi, Peng Gu, Haixing Feng, Fuling Wu, Lianbing Hou,∗Chuqi Hou∗, Yuhao Li. Yinning Tablet, a hospitalized preparation of Chinese herbal formula for hyperthyroidism, ameliorates thyroid hormone-induced liver injury in rats: Regulation of mitochondria-mediated apoptotic signals.Journal of Ethnopharmacology, 252 (2020) 112602(IF5.195, 一区)
[7] Liying Ren, Xia Zhou, Xiaoqian Huang, Chunxia Wang*, Yuhao Li*. The IRS/PI3K/Akt signaling pathway mediates olanzapine-induced hepatic insulin resistance in male rats. Life Sciences 2019;217: 229–236 (IF 6.780,二区)
[8] Liying Ren, Dongmei Sun, Xia Zhou, Yifan Yang, Xiaoqian Huang, Yangxue Li, Chunxia Wang*, Yuhao Li*. Chronic treatment with the modified Longdan Xiegan Tang attenuates olanzapine-induced fatty liver in rats by regulating hepatic de novo lipogenesis and fatty acid beta-oxidation-associated gene expression mediated by SREBP-1c, PPAR-alpha and AMPK-alpha. Journal of Ethnopharmacology 2019;232:176–187(IF5.195, 一区)
[9] Xia Zhou, Liying Ren, Zhilin Yu, Xiaoqian Huang, Yuhao Li, Chunxia Wang*, The antipsychotics sulpiride induces fatty liver in rats via phosphorylation of insulin receptor substrate-1 at Serine 307-mediated adipose tissue insulin resistance, Toxicology and Applied Pharmacology, 2018, 345:66-74. (IF4.46, 二区)
[10] Yuanyi Wei, Xia Zhou, Liying Ren, Chunxia Wang*, Yuhao Li. The prolactin-release inhibitor paeoniflorin suppresses proliferation and induces apoptosis in prolactinoma cells via the mitochondria-dependent pathway. Journal of Cellular Biochemistry, 2018; 119(7):5704-5714. (IF4.48,三区)
[11] La L, Wang L, Qin F, Jiang J, He S, Wang C*, Li Y. Zhen-wu-tang ameliorates adenine-induced chronic renal failure in rats: regulation of Wnt/beta-catenin signaling through the canonical pathway in the kidneys. Zhen-wu-tang ameliorates adenine-induced chronic renal failure in rats: regulation of the canonical Wnt4/beta-catenin signaling in the kidneys. Journal of Ethnopharmacology. 2018;12;219:81-90.(IF 5.195, 一区)